8-K: DarioHealth Secures $25.6 Million in Private Placement to Drive Towards Profitability

DarioHealth announces a $25.6 million private placement aimed at achieving an operational cash flow positive run rate by the end of 2025.

Summary

• DarioHealth Corp. has successfully closed a $25.6 million private placement of convertible preferred stock.
• The funding was primarily secured from existing shareholders and accredited healthcare investors.
• The company intends to use the proceeds to extend its cash runway and execute its strategic plan.
• DarioHealth aims to achieve an operational cash flow positive run rate by the end of 2025.
• The company plans to continue building high-margin, scalable recurring revenues across B2B and pharma channels.
• As a result of the private placement, DarioHealth's proforma cash balance is $40.6 million as of the end of the third quarter of 2024.
• 18,805 shares of Preferred Stock were sold at $1,000 per share, with a conversion price of $0.73 and 6,800 shares of Preferred Stock were sold at $1,000 per share, with a conversion price of $0.83.
• The Preferred Stock provides that upon conversion to common stock, holders will be entitled to receive a 10% dividend payable in common stock each quarter for the first four quarters, for an aggregate stock dividend of up to 40%.

Sentiment

Score: 7

Explanation: The announcement is generally positive, highlighting a successful funding round and a clear path towards profitability. However, the forward-looking statements and associated risks temper the overall sentiment.

Positives

• The private placement strengthens DarioHealth's financial position.
• The company's existing shareholders demonstrated confidence in the company's strategy by participating in the placement.
• The funding supports the execution of long-term growth initiatives.
• DarioHealth is targeting operational cash flow positivity by the end of 2025.
• The company is focused on high-margin, scalable recurring revenues.

Risks

• The company's actual results may differ materially from forward-looking statements due to various factors, including regulatory approvals, product demand, and market acceptance.
• The success of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources could impact results.
• The company's filings with the U.S. Securities and Exchange Commission contain additional risks that could cause differences between actual results and forward-looking statements.

Future Outlook

DarioHealth aims to achieve an operational cash flow positive run rate by the end of 2025 and maintain its growth trajectory by focusing on high-margin, scalable recurring revenues across B2B and pharma channels.

Management Comments

• Erez Raphael, Chief Executive Officer of Dario, believes the financing can secure the projected operational cash flow positive run rate by the end of 2025.
• Steven Nelson, Chief Commercial Officer of Dario, believes the financing will empower the company to execute on its long-term growth strategy.

Industry Context

The announcement reflects a trend in the digital health industry where companies are seeking funding to scale their operations and achieve profitability, particularly in the chronic care management space.

Stakeholder Impact

• Shareholders: The private placement could dilute existing shareholders, but the company's focus on profitability could benefit them in the long term.
• Employees: The funding provides stability and supports the company's growth plans, potentially creating opportunities for employees.
• Customers: The company's continued investment in its platform could lead to improved services and solutions for customers.
• Investors: The company's focus on profitability could attract new investors.

Next Steps

• DarioHealth will use the funds to execute its strategic plan.
• The company will continue to focus on building high-margin, scalable recurring revenues across B2B and pharma channels.
• The company will seek stockholder approval for the conversion of the Preferred Stock.

Key Dates